The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Pfizer's earlier buy-in only gave it ex-US rights to rimegepant, already approved and on sale in the US as Nurtec ODT, so taking control of the entire company will give it full ownership of the ...

Migraine is the third most common illness in the world, with about 14 percent of the global population experiencing migraine ...

Qulipta currently has no reports of interacting with Nurtec, better known as Nurtec ODT (rimegepant). Both Qulipta and Nurtec ODT belong to a group of drugs called CGRP antagonists. Both drugs ...

Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...

Currently, AbbVie’s Ubrelvy (ubrogepant) and Pfizer’s Zavzpret (zavegepant) and Nurtec (rimegepant) are available for acute treatment in the US. To intensify the competition, novel drug ...

Thanks in part to several acquisitions, it has multiple new growth drivers in its lineup, including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical ...

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, ...

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...

Dr. Coric's background includes leading Biohaven to the successful FDA approval and market launch of Nurtec ODT for migraine treatment, as well as the progression of a second drug candidate ...